Written by Prashasti Singh | Edited by Avik Roy, New Delhi
UPDATED ON MAY 15, 2021 02:37 PM IST
According to the health ministry, there are a few characteristics of the virus in children that their guardians should be on the lookout for.
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Arpan Rai
UPDATED ON NOV 21, 2020 07:48 PM IST
The significant improvement in time taken for clinical cure suggests that favipiravir may be beneficial in mild-to-moderate Covid-19, the study states.
PUBLISHED ON OCT 10, 2020 10:04 AM IST
In May, Glenmark had received approval from DCGI to conduct phase 3 clinical trials in the country using a combination of antiviral drugs Favipiravir and Umifenovir as a potential Covid-19 treatment strategy
Hindustan Times, Bhubaneswar | By Debabrata Mohanty | Edited by Sparshita Saxena
UPDATED ON OCT 03, 2020 11:56 PM IST
Favipiravir is an antiviral drug that was developed for the treatment of resistant influenza virus in Japan. In case of Covid-19 patients with mild to moderate symptoms, the medicine has proved to be effective.
UPDATED ON AUG 17, 2020 05:17 PM IST
Fusion Health Care has a strong pan-India presence with a field force of 600 employees and an innovative portfolio of Critical Care & Cardio-Diabetes products.
UPDATED ON JUL 23, 2020 01:04 AM IST
One of the principal investigators said that they have observed patients randomised to favipiravir seemed to have a faster clinical cure.
UPDATED ON JUL 13, 2020 09:28 PM IST
The Drugs Controller General of India (DCGI) granted it approval for Covid-19 treatment under emergency use authorisation, which means since there is limited data available on the medicine’s performance on Covid-19 positive cases, doctors prescribing it would have to document the written consent of a patient.
Bengaluru | By Press Trust of India
PUBLISHED ON JUN 19, 2020 08:25 PM IST
The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.
UPDATED ON MAY 26, 2020 05:36 PM IST
Favipiravir is an oral antiviral drug approved in Japan since 2014 for treating novel or re-emerging influenza virus infections. Umifenovir is another oral antiviral drug licenced for the treatment and prophylaxis of influenza A and B infections in Russia and China.
UPDATED ON MAY 13, 2020 04:58 AM IST
Glenmark Pharmaceuticals Limited will be looking at recruiting patients from hospitals in the red zones of states such as Gujarat, Maharashtra and Delhi where the Covid-19 case load is high.
Hindustan Times, New Delhi | By HT Correspondent
UPDATED ON MAR 19, 2020 12:10 PM IST
An active ingredient called Favipiravir, that goes into Japanese anti-flu medicine called Avigan, was tested on over 300 Covid-19 patients in China.